Overview

Company Overview

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable.

The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.

Stock Data

MTNB Symbol
NYSE American Market
Market Cap
Price
Change
Volume

Upcoming Events

ASM Microbe 2019

San Francisco, CA

Poster Presentation  
   
Session Title: AAR06 - Novel Approaches: Therapies, Diagnostics and Drug Discovery 
  for Mycobacteria
Abstract Title: Oral Delivery of Amikacin-Lipid Nano-Crystal Formulations Safely and 
  Effectively Treat Mycobacteria Infections in a Mouse Model of Cystic 
  Fibrosis”
Session Date: Friday, June 21, 2019
Presentation Time:  11:00 am – 12:00 pm PT and 4:00 pm – 5:00 pm PT 
Presenter: Raphael Mannino, Ph.D. 
 
Oral Presentation  
   
Poster Talk Title: Preclinical Leads for TB and NTM Infections 
Presentation Title: Oral Delivery of Amikacin-Lipid Nano-Crystal Formulations Safely and 
  Effectively Treat Mycobacteria Infections in a Mouse Model of Cystic 
  Fibrosis”
Session Date: Friday, June 21, 2019
Presentation Time:  1:15 pm – 2:15 pm PT 
Presenter: Raphael Mannino, Ph.D. 
Location:  AAR Lounge and Learn, South, Level 2